Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Anemia and Ischemic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PHD2/EGLN1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PHD2/EGLN1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Active site conformation optimized. |
View EGLN1 Products |
| Gene Delivery | PHD2/EGLN1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View EGLN1 Products |
| Benchmark Ab | Anti-PHD2/EGLN1 Reference Antibody Recombinant positive control for western blot, ELISA, and IHC. |
View EGLN1 Products |
| Validator | PHD2/EGLN1 siRNA Set For knockdown verification and functional validation. |
View EGLN1 Products |
| Related Target A | HIF1A (HIF-1 alpha) Primary downstream substrate of PHD2-mediated hydroxylation and proteasomal degradation. |
View HIF1A Products |
| Related Target B | EGLN3 (PHD3) Homologous prolyl hydroxylase isoform required for selectivity profiling. |
View EGLN3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity Screening (PHD1 vs PHD2 vs PHD3) | High-purity, sequence-verified recombinant proteins for accurate IC50/Ki profiling. |
| Co-factor & Substrate Dependency Validation | Proteins verified for enzymatic assay compatibility with 2-oxoglutarate and iron co-factors. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live PHD2/EGLN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the PHD2/EGLN1 pathway has revolutionized the management of chronic kidney disease (CKD)-associated anemia. By inhibiting PHD2, small molecules stabilize hypoxia-inducible factor (HIF) alpha subunits, mimicking physiological hypoxia to stimulate endogenous erythropoietin (EPO) production and optimize iron metabolism.
"The race for PHD2 therapeutics is intensifying, with major players shifting focus from traditional erythropoiesis-stimulating agents (ESAs) to oral HIF-PH inhibitors. As first-generation therapies reach the clinic, the next wave of R&D is targeting tissue-specific delivery, oncology indications, and cardioprotection."
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (HIF-PHI) | FibroGen, GSK, Akebia Therapeutics, Bayer | CKD Anemia, Ischemic Stroke, Inflammatory Bowel Disease | Enzymatic Selectivity Assay (Need recombinant PHD2, PHD1, and PHD3 panel) |
| Gene Therapy / RNAi | Academic institutions, Biotech startups | Myocardial Infarction, Wound Healing | Expression Validation (Need Lentivirus and siRNA validation tools) |